Organization (Industry)
Hoffmann-La Roche
ClinicalTrials.gov lists Hoffmann-La Roche as lead sponsor of 2,095 trials. It has 997 active development programs and 346 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 65 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 64 in 2026 and about 59 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 65 already registered with a 2026 start date: at the cutoff, 16 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.
Logo F. Hoffmann-La Roche, Ltd., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Hoffmann-La Roche: 2,095 lead-sponsored trials and 0 legal-entity registrations.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (599)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Breast Neoplasms | 435 |
| Lung Neoplasms | 296 |
| Lymphoma | 260 |
| Carcinoma, Non-Small-Cell Lung | 239 |
| Lymphoma, Non-Hodgkin | 229 |
Showing 5 of 599 disease areas.
Trials by start year as sponsor or collaborator (33)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 65 |
| 2025 | 56 |
| 2024 | 50 |
| 2023 | 82 |
| 2022 | 70 |
| 2021 | 115 |
| 2020 | 107 |
| 2019 | 77 |
| 2018 | 110 |
| 2017 | 99 |
Showing 10 of 33 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 96 trials still running at the 2026-10-09 snapshot; registered median of 29 months across 1,830 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (997)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Tocilizumab | Lymphoma | Phase 3 | 19 |
| Inavolisib | Breast Neoplasms | Phase 3 | 10 |
| Glofitamab | Lymphoma | Phase 3 | 14 |
| Obinutuzumab | Lymphoma | Phase 3 | 33 |
| Tocilizumab | Lymphoma, Non-Hodgkin | Phase 3 | 15 |
Showing 5 of 997 active programs.
Approved assets (346)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| ATEZOLIZUMAB | 138 |
| Tocilizumab | 112 |
| BEVACIZUMAB | 97 |
| RITUXIMAB | 80 |
| TRASTUZUMAB | 65 |
Showing 5 of 346 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 51% hit target (n=472) | 41% on time (n=497) |
Journals published in (955)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 301 |
| The New England journal of medicine | 234 |
| The Lancet. Oncology | 139 |
| Annals of oncology : official journal of the European Society for Medical Oncology | 126 |
| Blood | 112 |
Showing 5 of 955 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 9,119 | 934 | 2025-12-30 |
Financing and grant events (3)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2022-08-31 | NIH grant | 260,757 | Reporter |
| 2021-07-09 | NIH grant | 256,284 | Reporter |
| 2020-08-31 | NIH grant | 251,057 | Reporter |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 4 | 2009-11-13 |
Organization relationships (659)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| M.D. Anderson Cancer Center | Co sponsors trial with | 45 |
| Government of the United States of America | Co sponsors trial with | 34 |
| Bristol Myers Squibb Co | Co sponsors trial with | 24 |
| Chugai Pharmaceutical Co., Ltd. (Japan) | Co sponsors trial with | 23 |
| SCRI Development Innovations, LLC | Co sponsors trial with | 19 |
Showing 5 of 659 relationships.
Latest dated events (13,838)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 13,838 events.
Biomarker capability evidence (8,041)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AATF | Trial sponsor | Named in trial inclusion criteria |
| ABL1 | Trial sponsor | Primary endpoint in a Phase 3 trial |
| ABO | Trial collaborator | Named in trial inclusion criteria |
| ABR | Trial sponsor | Primary endpoint in a Phase 3 trial |
| ABR | Trial sponsor | Primary endpoint in a Phase 3 trial |
Showing 5 of 8,041 evidence rows.
Biomarkers this organization publishes on (431)
Shown in this order: most publications first.
Showing 5 of 431 biomarkers.
On Scientist.com
Hoffmann-La Roche is listed as a research supplier in the Scientist.com network.
Service areas
Today, I have the distinct privilege of leading the more than 1,200 researchers and scientists and 135 post-docs who are carrying on this impressive tradition. Genentech scientists are encouraged to be creative and active members of the scientific community. We are proud of our publication record in Science, Nature, Cell, and other prestigious peer-reviewed journals, where our annual output consistently rivals or surpasses that of the top academic institutions. Our novel discoveries have also secured more than 10,500 patents worldwide, with about 7,000 patent applications pending...
Show the full description
Today, I have the distinct privilege of leading the more than 1,200 researchers and scientists and 135 post-docs who are carrying on this impressive tradition.
Genentech scientists are encouraged to be creative and active members of the scientific community. We are proud of our publication record in Science, Nature, Cell, and other prestigious peer-reviewed journals, where our annual output consistently rivals or surpasses that of the top academic institutions. Our novel discoveries have also secured more than 10,500 patents worldwide, with about 7,000 patent applications pending.
Publications and patents, however, are means at Genentech, not ends. The primary mission of Genentech Research and Early Development is to keep the product pipeline full of new drug candidates for serious and life-threatening diseases. While perhaps best known for our work in oncology, which remains a major focus area, we have major initiatives ongoing in the areas of immunology, neuroscience, metabolism, and infectious disease. I truly believe that if your goal is to do world-class science in the interest of helping patients, there is no better place in the world to be.
- Website
- www.gene.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with Genentech on Scientist.com
For prices, more details, or to contact Genentech, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.